Primary syphilis

Summary

Primary syphilis (MONDO:0002896) is a disease and 3 clinical trials. Top therapeutic interventions include linezolid. A subtype of syphilis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	primary syphilis
Mondo ID	MONDO:0002896
MeSH	C536772
DOID	DOID:4156
NCIT	C128412
SNOMED CT	186846005
UMLS	C2931317
MedGen	419772
GARD	0027623
Is cancer (heuristic)	no

Also known as: early syphilis, symptomatic

Disease family

This is a subtype of syphilis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › primary bacterial infectious disease › syphilis › primary syphilis

Related subtypes (9): bejel, secondary syphilis, tertiary syphilis, congenital syphilis, latent syphilis, yaws, cutaneous syphilis, syphilitic aortitis, chancre

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05069974	PHASE3	ACTIVE_NOT_RECRUITING	Alternative Antibiotics for Syphilis
NCT01540227	Not specified	TERMINATED	Penicillin Therapeutic Drug Monitoring in the Treatment of Infectious Syphilis.
NCT05831098	Not specified	COMPLETED	Evaluation of the Sensitivity, Specificity, and Utility of the Reveal® TP (Syphilis) Antibody POCT

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LINEZOLID	4	1